Helus Pharma, doing business as the name for the company previously known as Cybin, is a clinical-stage biopharmaceutical company developing novel psychedelic-inspired therapeutics for mental health conditions. Its pipeline features deuterated psilocybin analogs and DMT derivatives designed as second-generation serotonergic agonists targeting major depressive disorder and generalized anxiety disorder. The company advances these candidates through clinical trials with a focus on improved pharmacological properties.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -24.6 | — |
| Q3 2025 | 0 | — | -33.7 | — |
| Q4 2025 | 0 | — | -42.7 | — |
| Q1 2026 | 0 | — | -47 | — |
| Q2 2026 | 0 | — | -47.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: EverQuote, Inc. (EVER), Peapack-Gladstone Financial Corporation (PGC), GCM Grosvenor Inc. (GCMG), Chaince Digital Holdings Inc. (CD), PubMatic, Inc. (PUBM), Collegium Pharmaceutical, Inc. (COLL)